CEL-SCI (NYSE:CVM) Trading Down 2.5%

Shares of CEL-SCI Co. (NYSE:CVM) traded down 2.5% during mid-day trading on Wednesday . The company traded as low as $1.16 and last traded at $1.19. 103,219 shares changed hands during trading, a decline of 67% from the average session volume of 311,925 shares. The stock had previously closed at $1.22.

Wall Street Analyst Weigh In

Separately, StockNews.com downgraded shares of CEL-SCI from a “hold” rating to a “sell” rating in a research report on Friday, March 15th.

CEL-SCI Stock Performance

The company has a current ratio of 1.67, a quick ratio of 1.18 and a debt-to-equity ratio of 0.63. The business’s 50 day moving average is $1.27 and its two-hundred day moving average is $1.86. The company has a market cap of $68.51 million, a PE ratio of -2.01 and a beta of 0.66.

CEL-SCI (NYSE:CVM) last released its earnings results on Thursday, May 16th. The company reported ($0.14) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.14). On average, equities research analysts anticipate that CEL-SCI Co. will post -0.51 EPS for the current year.

Insider Activity at CEL-SCI

In other news, Director Robert Eugene Watson bought 20,000 shares of the stock in a transaction that occurred on Wednesday, May 8th. The shares were bought at an average price of $1.39 per share, for a total transaction of $27,800.00. Following the purchase, the director now owns 24,431 shares in the company, valued at $33,959.09. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Robert Eugene Watson purchased 20,000 shares of the firm’s stock in a transaction on Wednesday, May 8th. The shares were acquired at an average price of $1.39 per share, for a total transaction of $27,800.00. Following the purchase, the director now directly owns 24,431 shares in the company, valued at $33,959.09. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Geert R. Kersten purchased 30,000 shares of the firm’s stock in a transaction on Wednesday, May 8th. The stock was bought at an average price of $1.39 per share, for a total transaction of $41,700.00. Following the purchase, the chief executive officer now owns 1,195,309 shares in the company, valued at $1,661,479.51. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 58,000 shares of company stock worth $80,620. 16.24% of the stock is owned by corporate insiders.

Institutional Trading of CEL-SCI

A number of large investors have recently made changes to their positions in the business. Chilton Capital Management LLC increased its holdings in shares of CEL-SCI by 297.4% in the 1st quarter. Chilton Capital Management LLC now owns 16,302 shares of the company’s stock worth $31,000 after buying an additional 12,200 shares during the last quarter. Tidal Investments LLC bought a new position in CEL-SCI during the 1st quarter valued at about $27,000. Tower Research Capital LLC TRC grew its holdings in CEL-SCI by 2,011.9% during the 4th quarter. Tower Research Capital LLC TRC now owns 16,198 shares of the company’s stock valued at $44,000 after purchasing an additional 15,431 shares during the last quarter. Forthright Family Wealth Advisory LLC bought a new position in CEL-SCI during the 4th quarter valued at about $45,000. Finally, Sheets Smith Wealth Management bought a new position in CEL-SCI during the 4th quarter valued at about $54,000. 12.08% of the stock is currently owned by institutional investors.

CEL-SCI Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.